Bipartisan political squabbling over drug prices has already cost biotech companies $21 billion

Michael Brush does the math and says that could have funded the development of 15 to 20 drugs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.